Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

UGN-501

Other · developed by UroGen Pharma, Inc., a subsidiary of UroGen Pharma

Phase 1 Most advanced trial
URGN Developer
1 Registered trials

What is UGN-501?

UGN-501 is administered by intravesical instillation into the bladder. It is being studied in non-muscle invasive bladder cancer, including urothelial carcinoma in situ and recurrent urothelial carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Oncology
Developer
UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd. (URGN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07725796 Phase 1 Bladder (Urothelial, Transitional Cell) Cancer Recruiting URGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Bladder (Urothelial, Transitional Cell) CancerNMIBCNon-muscle Invasive Bladder Cancer (NMIBC)Non-Muscle Invasive Bladder CarcinomaUrothelial Carcinoma BladderUrothelial Carcinoma in SituUrothelial Carcinoma of the Urinary BladderUrothelial Carcinoma Recurrent

More from UroGen Pharma, Inc., a subsidiary of UroGen Pharma

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the URGN page.

Follow URGN, the company behind UGN-501

See URGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

URGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.